Industrial Transformation Research Hubs - Grant ID: IH210100051
Funder
Australian Research Council
Funding Amount
$5,000,000.00
Summary
The ARC Research Hub for Digital Bioprocess Development. The ARC Hub for Digital Bioprocess Development aims to assist the Biopharma industry by increasing digital innovation, productivity and competitiveness. An interdisciplinary team of engineers, scientists and computing specialists will develop digitally integrated advanced manufacturing processes and a platform for industry adoption. The program will address key bioprocessing research challenges and develop new process and digital models th ....The ARC Research Hub for Digital Bioprocess Development. The ARC Hub for Digital Bioprocess Development aims to assist the Biopharma industry by increasing digital innovation, productivity and competitiveness. An interdisciplinary team of engineers, scientists and computing specialists will develop digitally integrated advanced manufacturing processes and a platform for industry adoption. The program will address key bioprocessing research challenges and develop new process and digital models that can predict and optimise manufacturing processes, resulting in greater yields, faster and more flexible processes and enhanced product stability. The Hub will transform biopharmaceutical manufacturing and unlock growth opportunities to forge an internationally competitive Australian Biopharma sector.Read moreRead less
ARC Centre of Excellence for Innovations in Peptide and Protein Science. The ARC Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS) strives to build a critical understanding of peptides and proteins in order to unleash the potential of these biomolecules for human benefit. We will discover nature’s untapped reservoir of peptides and proteins, decode their structures and functions, and
develop enhanced synthetic technologies to address biology’s next grand challenge—the d ....ARC Centre of Excellence for Innovations in Peptide and Protein Science. The ARC Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS) strives to build a critical understanding of peptides and proteins in order to unleash the potential of these biomolecules for human benefit. We will discover nature’s untapped reservoir of peptides and proteins, decode their structures and functions, and
develop enhanced synthetic technologies to address biology’s next grand challenge—the design of peptides and proteins for targeted scientific, agricultural, biotechnology, animal health and pharmaceutical applications. CIPPS will assemble leading researchers from diverse disciplines to create a sustainable national entity that will drive new Australian industries and train next generation researchers.Read moreRead less
A New Platform for Developing a Compound Against Herpes Simplex Virus. This project aims to further explore the research team’s recent fundamental discovery of a protein found naturally in an Australian abalone that inhibits viral entry by blocking three key viral glycoproteins. We would aim to utilise this knowledge towards development of a new class of therapeutics against Herpes simplex viruses (HSV) and their consequent infections. The new therapeutics could overcome the low bioavailability ....A New Platform for Developing a Compound Against Herpes Simplex Virus. This project aims to further explore the research team’s recent fundamental discovery of a protein found naturally in an Australian abalone that inhibits viral entry by blocking three key viral glycoproteins. We would aim to utilise this knowledge towards development of a new class of therapeutics against Herpes simplex viruses (HSV) and their consequent infections. The new therapeutics could overcome the low bioavailability of current drugs and thus significantly shorten the recurrence period. Such new drugs may have broad applicability.Read moreRead less
Rapid method development in pharmaceutical analysis using quality-by-design principles. Chemical analysis using separation methods underpins all stages of drug design and analysis. This project will generate new approaches to greatly reduce the time taken to develop a new method of analysis. This will be achieved through development of new computerised techniques for rapid screening, selection and optimisation of analytical methods.
Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innov ....Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innovative bioreactor to achieve high yield. It will research industrial biotransformations, providing a greener and cheaper process for increased global access to Codeine. Australian opiate manufacturing is expected to benefit from value adding and increased flexibility introduced by a biotechnology approach.Read moreRead less
Designing dendrimer-based lymphatic drug vectors as improved treatments for metastatic cancer. This project builds on areas of research strength in Australia (nanotechnology and biotechnology/biomaterials) and will add considerably to the expanding Australian expertise-base in dendrimer technology (in which it is a world leader). The project will advance the fundamental science base that underpins dendrimer design and has the potential to deliver substantial benefits in improved drug delivery an ....Designing dendrimer-based lymphatic drug vectors as improved treatments for metastatic cancer. This project builds on areas of research strength in Australia (nanotechnology and biotechnology/biomaterials) and will add considerably to the expanding Australian expertise-base in dendrimer technology (in which it is a world leader). The project will advance the fundamental science base that underpins dendrimer design and has the potential to deliver substantial benefits in improved drug delivery and therefore health outcomes for Australia. The interdisciplinary nature of this project will also result in a unique training program for the researchers involved. Such experience is in great demand in Australia where the developing biotechnology and nanotechnology industry is critically short of scientists with skills in drug delivery.Read moreRead less
Controlling the spatial distribution of targeting ligands on dendrimer surfaces as a means of dictating cellular recognition and fate. This project seeks to develop next generation targeted drug delivery systems that 'home' to specific target cells, including cancers. Targeted delivery systems have the potential to revolutionise therapy by providing bespoke drug distribution patterns that are tailored to specific diseases and result in enhanced activity and reduced toxicity.
Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficac ....Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficacious and stable formulations of bacteriophages for easy delivery by inhalation as aerosols with a long shelf-life, making them a commercially viable product. The expected research outcome can lead to an economic and efficient technology to produce phage powders for novel treatment strategies of infections by inhalation.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100020
Funder
Australian Research Council
Funding Amount
$3,279,502.00
Summary
ARC Training Centre for the Chemical Industries . The ARC Training Centre for the Chemical Industries will foster a world-class environment of transformative innovative research in Australia’s chemical and advanced manufacturing industry through sustained partnerships with universities. The Centre establish a new industry-led HDR graduate program. The research activities of the Centre aim to improve chemical analytical and manufacturing capabilities, new biopharmaceuticals, enhanced global compe ....ARC Training Centre for the Chemical Industries . The ARC Training Centre for the Chemical Industries will foster a world-class environment of transformative innovative research in Australia’s chemical and advanced manufacturing industry through sustained partnerships with universities. The Centre establish a new industry-led HDR graduate program. The research activities of the Centre aim to improve chemical analytical and manufacturing capabilities, new biopharmaceuticals, enhanced global competitive advantages, and long-term growth and intellectual property development in the chemistry industry. Other national benefits include up-skilled, workplace-ready graduates with experience in conducting industry-focused research.Read moreRead less
Pilot-scale production of therapeutically-active cannabinoids . The Isolation of minor therapeutically-active cannabinoids from cannabis at pilot scale would establish a commercially competitive Australian industry and lead to a superior position in the global marketplace. This project aims to select elite clones from genetically diverse cannabis strains for yield of minor, but therapeutically-active, cannabinoids, and develop a pilot-scale extraction and separation procedure that can be scaled- ....Pilot-scale production of therapeutically-active cannabinoids . The Isolation of minor therapeutically-active cannabinoids from cannabis at pilot scale would establish a commercially competitive Australian industry and lead to a superior position in the global marketplace. This project aims to select elite clones from genetically diverse cannabis strains for yield of minor, but therapeutically-active, cannabinoids, and develop a pilot-scale extraction and separation procedure that can be scaled-up for commercial production. This would contribute to the growth of the agri-biotechnology sector and a skilled multidisciplinary workforce in rural Australia, thus providing significant economic benefit. The novel scale-up procedure has potential for industry adoption to add value to Australian manufacturing.
Read moreRead less